Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DCT002
MIFTS: 55

Ductal Carcinoma in Situ

Categories: Cancer diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Ductal Carcinoma in Situ

About this section

MalaCards integrated aliases for Ductal Carcinoma in Situ:

Name: Ductal Carcinoma in Situ 11 28 5 14 75
Noninfiltrating Intraductal Carcinoma 71

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 11 DOID:0060074
UMLS 71 C0007124
Sources

Summaries for Ductal Carcinoma in Situ

About this section

Disease Ontology: 11 A breast carcinoma in situ that is characterized by being non-invasive, not having spread outside of the duct into the surrounding breast tissue, has material basis in abnormally proliferating cells, derives from epithelial cells.

MalaCards based summary: Ductal Carcinoma in Situ, also known as noninfiltrating intraductal carcinoma, is related to comedo carcinoma and breast ductal carcinoma. An important gene associated with Ductal Carcinoma in Situ is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Disease and Signaling by Receptor Tyrosine Kinases. The drugs Ropivacaine and Ondansetron have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and skin, and related phenotypes are Decreased viability and homeostasis/metabolism

Wikipedia: 75 Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma, is a pre-cancerous or non-invasive... more...
Sources

Related Diseases for Ductal Carcinoma in Situ

About this section

Diseases related to Ductal Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 572)
# Related Disease Score Top Affiliating Genes
1 comedo carcinoma 32.7 TP53 PGR KRT5 KRT14 ESR1 ERBB2
2 breast ductal carcinoma 31.9 TP53 PGR KRT5 KRT14 ESR1 ERBB2
3 mammary paget's disease 31.5 PGR ESR1 ERBB2
4 gynecomastia 31.5 PGR ESR1 ERBB2 CYP19A1
5 intraductal papilloma 31.4 PGR KRT5 KRT14 ESR1 ERBB2
6 breast cancer 31.4 TP53 SERPINA3 PGR MIR423 MIR342 MIR181A1
7 papilloma 31.4 TP53 KRT5 KRT14 ERBB2 EGFR CDH1
8 lobular neoplasia 31.3 TP53 PGR KRT5 ESR1 ERBB2 EGFR
9 tubular adenocarcinoma 31.3 PGR ESR1 ERBB2 CDH1
10 breast disease 31.2 TP53 SERPINA3 PGR MIR423 MIR342 MIR181A1
11 breast adenomyoepithelioma 31.2 KRT5 KRT14
12 breast fibroadenoma 31.1 TP53 SERPINA3 PGR KRT5 KRT14 ESR1
13 neuroendocrine carcinoma 31.1 PGR ESR1 CDH1
14 inherited cancer-predisposing syndrome 31.0 TP53 EGFR CDH1 BRCA2 BRCA1
15 bap1 tumor predisposition syndrome 31.0 TP53 EGFR CDH1 BRCA2 BRCA1
16 microglandular adenosis 31.0 SERPINA3 PGR ESR1 ERBB2
17 benign breast phyllodes tumor 30.9 PGR ESR1
18 breast-ovarian cancer, familial 2 30.9 BRCA2 BRCA1
19 hereditary breast cancer 30.9 CDH1 BRCA2 BRCA1
20 hereditary breast ovarian cancer syndrome 30.8 TP53 PGR ESR1 ERBB2 EGFR CYP19A1
21 diffuse gastric and lobular breast cancer syndrome 30.8 TP53 ERBB2 CDH1 BRCA2 BRCA1
22 breast carcinoma in situ 30.8 TP53 SERPINA3 PGR MIR423 MIR342 MIR181A1
23 adenoid cystic carcinoma 30.8 TP53 SERPINA3 PGR KRT14 ERBB2 EGFR
24 adenocarcinoma 30.7 TP53 ERBB2 EGFR CDH1 BRCA2 AKT1
25 bilateral breast cancer 30.7 TP53 PGR ESR1 ERBB2 CYP19A1 CDH1
26 female breast cancer 30.7 TP53 PGR KRT5 KRT14 ESR1 ERBB2
27 squamous cell carcinoma 30.7 TP53 KRT14 ERBB2 EGFR CDH1 AKT1
28 estrogen excess 30.7 PGR ESR1 CYP19A1
29 pleomorphic carcinoma 30.7 TP53 KRT5 EGFR
30 lymphoepithelioma-like carcinoma 30.7 TP53 KRT5 EGFR
31 vaginal discharge 30.7 PGR ESR1 CYP19A1
32 breast adenoid cystic carcinoma 30.7 PGR KRT5 ESR1 ERBB2
33 ovarian cyst 30.7 PGR ESR1 CYP19A1 BRCA1
34 exanthem 30.7 ERBB2 EGFR AKT1
35 vulva cancer 30.6 TP53 ERBB2 EGFR
36 endometrial cancer 30.6 TP53 PGR ESR1 ERBB2 EGFR CYP19A1
37 adenosquamous carcinoma 30.6 SERPINA3 PGR KRT5 EGFR
38 cribriform carcinoma 30.6 PGR KRT5 ESR1 ERBB2 EGFR
39 hypertrophy of breast 30.6 TP53 PGR KRT5 ESR1 ERBB2 EGFR
40 pleomorphic adenoma 30.6 TP53 KRT14 ERBB2
41 keratoacanthoma 30.6 TP53 KRT14 EGFR CDH1
42 papillary serous adenocarcinoma 30.5 TP53 PGR ESR1 ERBB2 BRCA2 BRCA1
43 prolactinoma 30.5 ESR1 ERBB2 EGFR CYP19A1 CDH1
44 breast secretory carcinoma 30.5 SERPINA3 KRT5
45 lymphatic system disease 30.5 TP53 SERPINA3 MIR423 MIR342 MIR181A1
46 small cell cancer of the lung 30.5 TP53 EGFR AKT1
47 sporadic breast cancer 30.5 TP53 PGR KRT5 ESR1 ERBB2 BRCA2
48 cardiovascular system disease 30.4 SERPINA3 MIR423 MIR342 MIR181A1 ESR1 AKT1
49 lymphoma, non-hodgkin, familial 30.4 TP53 SERPINA3 MIR423 MIR342 MIR181A1 AKT1
50 li-fraumeni syndrome 30.4 TP53 ESR1 ERBB2 EGFR CDH1 BRCA2

Graphical network of the top 20 diseases related to Ductal Carcinoma in Situ:



Diseases related to Ductal Carcinoma in Situ
Sources

Symptoms & Phenotypes for Ductal Carcinoma in Situ

About this section

GenomeRNAi Phenotypes related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

25 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.99 EGFR TNK2
2 Decreased viability GR00055-A-2 9.99 EGFR TNK2
3 Decreased viability GR00221-A-1 9.99 AKT1 CDH1 EGFR ESR1 TNK2
4 Decreased viability GR00221-A-2 9.99 AKT1 ESR1 TNK2
5 Decreased viability GR00221-A-3 9.99 AKT1 TNK2 ERBB2
6 Decreased viability GR00221-A-4 9.99 AKT1 EGFR ESR1 TNK2 ERBB2
7 Decreased viability GR00249-S 9.99 AKT1
8 Decreased viability GR00301-A 9.99 CDH1
9 Decreased viability GR00381-A-1 9.99 TNK2
10 Decreased viability GR00386-A-1 9.99 ESR1
11 Decreased viability GR00402-S-2 9.99 CDH1 ESR1

MGI Mouse Phenotypes related to Ductal Carcinoma in Situ:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.28 AKT1 BRCA1 BRCA2 CDH1 CLDN7 CT45A10
2 neoplasm MP:0002006 10.22 AKT1 BRCA1 BRCA2 CDH1 EGFR ERBB2
3 normal MP:0002873 10.21 AKT1 BRCA1 BRCA2 CDH1 CYP19A1 EGFR
4 endocrine/exocrine gland MP:0005379 10.14 AKT1 BRCA1 BRCA2 CDH1 CYP19A1 EGFR
5 muscle MP:0005369 10.1 AKT1 BRCA1 CYP19A1 EGFR ERBB2 ESR1
6 limbs/digits/tail MP:0005371 10.08 BRCA1 BRCA2 EGFR ERBB2 ESR1 KRT5
7 immune system MP:0005387 10.07 AKT1 BRCA1 BRCA2 CDH1 CYP19A1 EGFR
8 embryo MP:0005380 10.02 AKT1 BRCA1 BRCA2 CDH1 EGFR ERBB2
9 digestive/alimentary MP:0005381 10.02 BRCA1 BRCA2 CDH1 CYP19A1 EGFR ERBB2
10 adipose tissue MP:0005375 10 AKT1 BRCA1 CYP19A1 EGFR ESR1 KRT14
11 reproductive system MP:0005389 9.9 AKT1 BRCA1 BRCA2 CDH1 CYP19A1 EGFR
12 hematopoietic system MP:0005397 9.73 AKT1 BRCA1 BRCA2 CLDN7 CYP19A1 EGFR
13 integument MP:0010771 9.47 AKT1 BRCA1 BRCA2 CDH1 CLDN7 CYP19A1
Sources

Drugs & Therapeutics for Ductal Carcinoma in Situ

About this section

Drugs for Ductal Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 89)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
2
Ondansetron Approved, Withdrawn Phase 4 99614-02-5 4595
3
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
4 Dsuvia Phase 4
5 Anesthetics, Local Phase 4
6 Anesthetics, Intravenous Phase 4
7 Anesthetics, General Phase 4
8 Analgesics, Opioid Phase 4
9
Medroxyprogesterone acetate Approved, Investigational Phase 3 520-85-4, 71-58-9 6279 10631
10
Trastuzumab Approved, Investigational Phase 3 180288-69-1
11
Anastrozole Approved, Investigational Phase 3 120511-73-1 2187
12
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
13
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
14
Sodium citrate Approved, Investigational Phase 3 68-04-2 23431961
15
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
16 Contraceptives, Oral Phase 3
17 Contraceptive Agents Phase 3
18 Estrogens, Conjugated (USP) Phase 3
19 Contraceptives, Oral, Hormonal Phase 3
20 Contraceptive Agents, Male Phase 3
21 Immunologic Factors Phase 3
22 Aromatase Inhibitors Phase 3
23 Immunoglobulins, Intravenous Phase 3
24 Immunoglobulins Phase 3
25 Antibodies, Monoclonal Phase 3
26 Antibodies Phase 3
27 Trastuzumab biosimilar HLX02 Phase 3
28 Citrate Phase 3
29
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
30
Progesterone Approved, Vet_approved Phase 2 57-83-0 5994
31
Chloroquine Approved, Investigational, Vet_approved Phase 1, Phase 2 54-05-7 2719
32
Zoledronic acid Approved Phase 2 118072-93-8 68740
33
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
34
Polyestradiol phosphate Approved Phase 2 28014-46-2
35
Bazedoxifene Approved, Investigational Phase 2 198481-32-2 154257
36
Sargramostim Approved, Investigational Phase 2 123774-72-1
37
Metformin Approved Phase 2 1115-70-4, 657-24-9 4091
38
Oxytocin Approved, Vet_approved Phase 2 50-56-6 439302 53477758
39
Ethanol Approved Phase 2 64-17-5 702
40
Naltrexone Approved, Investigational, Vet_approved Phase 2 16590-41-3 5360515
41
Tamoxifen Approved Phase 2 10540-29-1, 54965-24-1 2733526
42
Fulvestrant Approved, Investigational Phase 2 129453-61-8 17756771 104741
43
Somatostatin Approved, Investigational Phase 1, Phase 2 38916-34-6, 51110-01-1 53481605 16129706
44
Pasireotide Approved Phase 1, Phase 2 396091-73-9 56841596 9941444
45
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
46
Sulforaphane Investigational Phase 2 4478-93-7, 142825-10-3 5350
47
Afimoxifene Investigational Phase 2 68392-35-8 63062
48
Molgramostim Investigational Phase 2 99283-10-0
49 Analgesics Phase 1, Phase 2
50 Antirheumatic Agents Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 111)
# Name Status NCT ID Phase Drugs
1 The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery. A Double Blind, Randomised, Placebo Controlled Trial. Unknown status NCT04248179 Phase 4 Ropivacaine injection;Saline 0.9%;Sufentanil and PONV prophylaxis
2 Electronic Xoft Intersociety Brachytherapy Trial Completed NCT00742222 Phase 4
3 Interstitial Brachytherapy Alone Versus External Beam Radiation Therapy After Breast Conserving Surgery for Low-risk Invasive Carcinoma and Low-risk Ductal Carcinoma in Situ (DCIS) of the Female Breast Unknown status NCT00402519 Phase 3
4 Evaluation of a New Intraoperative Gamma Camera for the Sentinel Lymph Node Procedure in Breast Cancer Completed NCT00757302 Phase 3
5 A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy In Postmenopausal Women With A History Of Node-Negative Or Ductal Carcinoma In Situ Who Are Receiving Adjuvant Tamoxifen Completed NCT00026286 Phase 3 conjugated estrogens;medroxyprogesterone
6 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
7 A Clinical Trial Comparing Anastrozole With Tamoxifen in Postmenopausal Patients With Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy With Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
8 Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk and Estrogen Receptor-Positive Ductal Carcinoma in Situ of Breast: an International Open-label Randomized Non-inferiority Trial Recruiting NCT04046159 Phase 3 Low-dose tamoxifen
9 A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy Active, not recruiting NCT00769379 Phase 3
10 A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer Active, not recruiting NCT01272037 Phase 3 Anastrozole;Exemestane;Letrozole;Systemic Chemotherapy;Tamoxifen Citrate
11 A Randomised Phase III Study of Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast Active, not recruiting NCT00470236 Phase 3
12 A Phase II Randomized Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ Unknown status NCT00669747 Phase 2 Carboplatin i.d. Days 1 & 15;Carboplatin i.d. Day 1; Normal Saline i.d. Day 15;Normal Saline
13 Randomised Trial Testing Observation (No Radiotherapy) Against Radiotherapy In Women With Low-Risk Completely Excised ER Positive Ductal Carcinoma In Situ (DCIS) Of The Breast On Adjuvant Endocrine Therapy Unknown status NCT00077168 Phase 2 anastrozole;tamoxifen citrate
14 Preventing Invasive Breast Neoplasia With Chloroquine (PINC) Trial Completed NCT01023477 Phase 1, Phase 2 Chloroquine Standard Dose (500mg/week);Chloroquine Low Dose (250mg/week)
15 A Phase II Prospective Pilot Study Evaluating Efficacy of Intravenous Zoledronic Acid Prophylaxis for Prevention of Aromatase Inhibitor Associated Musculoskeletal Symptoms: ZAP-AIMSS Trial Completed NCT01194440 Phase 2 letrozole;zoledronic acid
16 Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast. Completed NCT03002766 Phase 2
17 Randomized Phase II Biomarker Pilot Trial of Fluvastatin Use in Women With Ductal Carcinoma in Situ (DCIS) or Stage I Breast Cancer Completed NCT00416403 Phase 2 fluvastatin sodium
18 Sulforaphane: A Dietary Histone Deacetylase (HDAC) Inhibitor in Ductal Carcinoma in Situ (DCIS) Completed NCT00843167 Phase 2
19 MammoSite Radiation Therapy System (RTS) as the Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ (DCIS) Completed NCT00586326 Phase 2
20 Pre-surgical Phase IIb Trial of Transdermal 4-Hydroxytamoxifen vs. Oral Tamoxifen in Women With Ductal Carcinoma in Situ of the Breast Completed NCT00952731 Phase 2 oral placebo;afimoxifene;tamoxifen citrate;placebo gel
21 Primary Hormonal Therapy for Ductal Carcinoma in Situ: Exploration of a Novel Approach to the Clinical Management of Noninvasive Breast Cancer Completed NCT00290745 Phase 1, Phase 2 letrozole;tamoxifen citrate
22 Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS) Completed NCT01439711 Phase 2 letrozole
23 Positron Emission Tomography/Magnetic Resonance Imaging of Estrogen Receptor Expression n Non-Invasive Breast Cancer Recruiting NCT03703492 Phase 2 (18F)FES;Gadobenate dimeglumine
24 Volumetric Lumpectomy Specimen Image Visualization for Intraoperatively Directing Cavity Shaves, a Phase II Study (VIVID) Recruiting NCT05545150 Phase 2
25 Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ Recruiting NCT04666961 Phase 2 Tamoxifen 20 mg;Anastrozole 1Mg Tab
26 Intermittent Fasting for Patients With HER2- Negative and ER/PR <10% Breast Cancer and Body Mass Index >= 25 Receiving Neoadjuvant Chemotherapy Recruiting NCT05327608 Phase 2
27 Window Trial of Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer (a BEAUTY Study*) Recruiting NCT03979508 Phase 2 Abemaciclib
28 Pilot Study for the Cryoablation of Ductal Carcinoma In Situ: Subzero and Scorpion Trial Recruiting NCT05032079 Phase 2
29 TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions Recruiting NCT02928978 Phase 2 Ruxolitinib;Placebo (for Ruxolitinib)
30 SABR-CaRe: A Phase II Randomized Trial of Pre-Operative Stereotactic Ablative Radiation Therapy (SABR) With and Without Caloric Restriction for Early Stage Breast Cancer Recruiting NCT04959474 Phase 2
31 A Large-scale Multicenter Phase II Study Evaluating the Protective Effect of a Tissue Selective Estrogen Complex (TSEC) in Women With Newly Diagnosed Ductal Carcinoma in Situ Recruiting NCT02694809 Phase 2 Conjugated Estrogens/Bazedoxifene
32 VADIS Trial: Phase II Trial of Nelipeimut-S Peptide Vaccine in Women With DCIS of the Breast Active, not recruiting NCT02636582 Phase 2 Nelipepimut-S Plus GM-CSF Vaccine
33 Wide Excision Alone for DCIS-Grades 1 and 2 Active, not recruiting NCT00165256 Phase 2
34 Randomized Trial of Hypofractionated Whole Breast Irradiation Versus Conventionally Fractionated Whole Breast Irradiation for Ductal Carcinoma In Situ and Early Invasive Breast Cancer Active, not recruiting NCT01266642 Phase 2
35 Time Restricted Eating And Metformin (TEAM) in Invasive Breast Cancer (IBC) or Ductal Carcinoma in Situ (DCIS). A Randomized, Phase IIb, Window of Opportunity Presurgical Trial. Not yet recruiting NCT05023967 Phase 2 Extended Release Metformin Hydrochloride
36 Identifying the miR Fingerprint in NAF, Serum, and Tissue in Patients With Ductal Carcinoma in Situ (DCIS) or Invasive Breast Cancer Suspended NCT02127073 Phase 2 Intranasal Oxytocin
37 Naltrexone Randomized Controlled Trial for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer Terminated NCT02137252 Phase 2 Naltrexone;Sugar Pill
38 An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy Terminated NCT02540330 Phase 2 Fulvestrant
39 A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ (DCIS) Terminated NCT01060345 Phase 2 Polyphenon E
40 Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor Terminated NCT01372618 Phase 1, Phase 2 SOM 230 / Pasireotide
41 A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS) Terminated NCT00183963 Phase 2 Tamoxifen;Fulvestrant
42 A Pilot Study of Stereotactic Accelerated Partial Breast Irradiation (SAPBI) for Post-Menopausal Women (>50 y/o) With Ductal Carcinoma in Situ (DCIS) or Early Stage Breast Cancer Terminated NCT02365714 Phase 1, Phase 2
43 Twin Cities Brachytherapy Study for Ductal Carcinoma in Situ A Phase II Trial Terminated NCT00290654 Phase 2 Tamoxifen
44 EGFR Pathway Modulation In Patients With Ductal Carcinoma In Situ Of The Breast Terminated NCT00082667 Phase 2 gefitinib
45 Phase I/II Study Evaluating Safety and Effects of Preoperative High-Dose Vitamin D on the Receptors, Biomarkers and Pathological Characteristics of High Grade DCIS or Invasive Breast Cancer. Withdrawn NCT02856503 Phase 1, Phase 2 Vitamin D3
46 Improvement of the Operative Outcome in Patients With Primary VEGF Positive Unifocal Breast Cancer or Ductal Carcinoma in Situ (DCIS) Through the Intraoperative Visualization of the Tumor Using Molecular Imaging and Fluorescent Markers Bevacizumab-IRDye-800CW Withdrawn NCT05359874 Phase 2 Bevacizumab-IRDye800CW
47 A Window Trial of Vorinostat in Patients With Ductal Carcinoma in Situ (DCIS) of the Breast Completed NCT00788112 Phase 1 vorinostat
48 A Phase IB Trial of Neoadjuvant Multi-Epitope HER2 Peptide Vaccine in Patients With HER2-Expressing DCIS Recruiting NCT04144023 Phase 1
49 A Randomized Clinical Trial Comparing Supplemental Topical Treatments for Acute Radiation Dermatitis in Breast Cancer Patients Recruiting NCT05340673 Phase 1 Agent Affecting Integumentary System
50 Phase I Trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery Active, not recruiting NCT03317405 Phase 1 Endoxifen Hydrochloride

Search NIH Clinical Center for Ductal Carcinoma in Situ

Sources

Genetic Tests for Ductal Carcinoma in Situ

About this section

Genetic tests related to Ductal Carcinoma in Situ:

# Genetic test Affiliating Genes
1 Ductal Carcinoma in Situ 28
Sources

Anatomical Context for Ductal Carcinoma in Situ

About this section

Organs/tissues related to Ductal Carcinoma in Situ:

MalaCards : Breast, Lymph Node, Skin, Salivary Gland, Smooth Muscle, Myeloid, Endothelial
Sources

Publications for Ductal Carcinoma in Situ

About this section

Articles related to Ductal Carcinoma in Situ:

(show top 50) (show all 7527)
# Title Authors PMID Year
1
Ductal carcinoma in situ of the breast arising in a solitary intraductal papilloma. 62
36439917 2023
2
A comparison of the imaging appearance of breast cancer in African American women with non-Latina white women. 62
36413877 2023
3
Financial Toxicity of Breast Cancer Care: The Patient Perspective Through Surveys and Interviews. 62
36155269 2023
4
Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies. 62
36473870 2022
5
Relative Survival With Early-Stage Breast Cancer in Screened and Unscreened Populations. 62
36336518 2022
6
Contrast-Enhanced Mammography Versus MRI in the Evaluation of Neoadjuvant Therapy Response in Patients With Breast Cancer: A Prospective Study. 62
35731101 2022
7
Definitive radiotherapy with stereotactic or IMRT boost with or without radiosensitization strategy for operable breast cancer patients who refuse surgery. 62
35849134 2022
8
Loss of Epigenetic Regulation Disrupts Lineage Integrity, Induces Aberrant Alveogenesis, and Promotes Breast Cancer. 62
36108220 2022
9
Clinicopathologic Features, Treatment Patterns, and Disease Outcomes in a Modern, Prospective Cohort of Young Women Diagnosed with Ductal Carcinoma In Situ. 62
35960452 2022
10
Precise application of sentinel lymph node biopsy in patients with ductal carcinoma in situ: A systematic review and meta-analysis of real-world data. 62
36332555 2022
11
Learning to distinguish progressive and non-progressive ductal carcinoma in situ. 62
36261705 2022
12
Predicting ipsilateral recurrence in women treated for ductal carcinoma in situ using machine learning and multivariable logistic regression models. 62
36257084 2022
13
Outcome and risk factors for local recurrence after breast conserving surgery in patients affected by ductal carcinoma in situ. 62
35230036 2022
14
Breast cancer early detection by using Fourier-transform infrared spectroscopy combined with different classification algorithms. 62
35985225 2022
15
ASO Visual Abstract: Clinicopathologic Features, Treatment Patterns, and Disease Outcomes in a Modern, Prospective Cohort of Young Women Diagnosed with Ductal Carcinoma In Situ. 62
36038744 2022
16
The presentation, management and outcome of patients with ductal carcinoma in situ (DCIS) with microinvasion (invasion ≤1 mm in size)-results from the UK Sloane Project. 62
36224403 2022
17
Integrating age, BMI, and serum N-glycans detected by MALDI mass spectrometry to classify suspicious mammogram findings as benign lesions or breast cancer. 62
36460712 2022
18
Improving well-being for individuals with persistent pain after surgery for breast cancer, lobular carcinoma in situ, or ductal carcinoma in situ: A randomized clinical trial. 62
36152791 2022
19
Risk of Anaplastic Large Cell Lymphoma Following Postmastectomy Implant Reconstruction in Women With Breast Cancer and Ductal Carcinoma in Situ. 62
36413370 2022
20
ASO Visual Abstract: Overuse of Axillary Surgery for Patients With Ductal Carcinoma In Situ: Opportunity for De-Escalation. 62
35876930 2022
21
Changes in Serum Trace Element Concentrations Before and After Surgery in Resectable Breast Cancer. 62
36288886 2022
22
Prognostic significance of microinvasion with ductal carcinoma in situ of the breast: a meta-analysis. 62
36427119 2022
23
Expression of HLA class I is associated with immune cell infiltration and patient outcome in breast cancer. 62
36437379 2022
24
Sweat Gland Carcinoma With Neuroendocrine Differentiation of the Areola as a Potential Clinicopathologic Mimicker of Male Breast Carcinoma and Syringocystadenocarcinoma Papilliferum. 62
35925548 2022
25
Detection of Epstein Barr Nuclear Antigen-1 (EBNA-1), Early Antigen 1F, 2R (EA-1F, EA- 2R) along with Epstein-Barr virus Latent Membrane Protein 1 (LMP1) in Breast Cancer of Northern India: An Interim Analysis. 62
36444584 2022
26
Diffusion-weighted Breast MRI in Prediction of Upstaging in Women with Biopsy-proven Ductal Carcinoma in Situ. 62
35787199 2022
27
Impact of Surgical Delay on Tumor Upstaging and Outcomes in Estrogen Receptor-Negative Ductal Carcinoma in Situ Patients. 62
36102573 2022
28
Survival outcomes after breast-conserving surgery plus radiotherapy compared with mastectomy in breast ductal carcinoma in situ with microinvasion. 62
36418384 2022
29
Evaluating Upstaging in Ductal Carcinoma In Situ Using Preoperative MRI-Based Radiomics. 62
36440711 2022
30
Spatial genomics maps the structure, nature and evolution of cancer clones. 62
36352222 2022
31
Contrast-enhanced mammography for the assessment of screening recalls: a two-centre study. 62
35648209 2022
32
Is loss of p53 a driver of ductal carcinoma in situ progression? 62
35764786 2022
33
Overuse of Axillary Surgery in Patients with Ductal Carcinoma In Situ: Opportunity for De-escalation. 62
35789303 2022
34
The Role of Diffusion-weighted Imaging in Biopsy-proven Ductal Carcinoma in Situ. 62
35787207 2022
35
Potential of specimen diffusion-weighted imaging to assess the intraoperative margin for ductal carcinoma in situ and invasive breast cancer. 62
36394392 2022
36
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts. 62
36400020 2022
37
Risk factors for breast cancer mortality after ductal carcinoma in situ diagnosis differ from those for invasive recurrence. 62
36435650 2022
38
Oncoplastic Breast Surgery versus Conservative Mastectomy in the Management of Large Ductal Carcinoma In Situ (DCIS): Surgical, Oncological, and Patient-Reported Outcomes. 62
36428718 2022
39
Ductal carcinoma in situ of the male breast: clinical radiological features and management in a cancer referral center. 62
36114939 2022
40
Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial. 62
36069821 2022
41
Oncological Safety of Skin-Sparing Mastectomy and Immediate Breast Reconstruction in Extensive Ductal Carcinoma In Situ. 62
35717793 2022
42
Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience. 62
36083381 2022
43
External Validation of an Ensemble Model for Automated Mammography Interpretation by Artificial Intelligence. 62
36409497 2022
44
Surgical management of breast cancer in Victoria: A state-wide audit. 62
36373172 2022
45
Dimorphic cells: a common feature throughout the low nuclear grade breast neoplasia spectrum. 62
36378325 2022
46
Gestational Hypertensive Disorders and Maternal Breast Cancer Risk in a Nationwide Cohort of 40,720 Parous Women. 62
35648421 2022
47
Outcomes and toxicities after proton partial breast radiotherapy for early stage, hormone receptor positive breast cancer: 3-Year results of a phase II multi-center trial. 62
36093343 2022
48
Factors Associated With Cosmetic Outcomes After Treatment With a Novel Form of Breast Intraoperative Radiation Therapy. 62
36436288 2022
49
Presence of Non-classic LCIS Is Not a Contraindication to Breast Conservation in Patients with Concomitant Invasive Breast Cancer or DCIS. 62
35771367 2022
50
Treatment of Mammary Paget Disease: A systematic review and meta-analysis of real-world data. 62
36309195 2022
Sources

Variations for Ductal Carcinoma in Situ

About this section

ClinVar genetic disease variations for Ductal Carcinoma in Situ:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln) SNV Pathogenic
 12356 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220

Cosmic variations for Ductal Carcinoma in Situ:

8 (show top 50) (show all 369)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM149317650 ZFHX3 breast,NS,carcinoma in situ,ductal carcinoma in situ c.2403A>T p.K801N 16:72957743-72957743 7
2 COSM87291166 ZFHX3 breast,NS,carcinoma in situ,ductal carcinoma in situ c.2403A>T p.K801N 16:72957743-72957743 7
3 COSM102041732 ZFHX3 breast,NS,carcinoma in situ,ductal carcinoma in situ c.-23-6778A>T p.? 16:72957743-72957743 7
4 COSM143944147 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.265C>T p.R89W 17:7674221-7674221 7
5 COSM112254852 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.584T>C p.I195T 17:7674947-7674947 7
6 COSM122733862 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.422G>A p.R141H 17:7673802-7673802 7
7 COSM144092525 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.110G>C p.R37P 17:7674944-7674944 7
8 COSM112253807 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.733G>A p.G245S 17:7674230-7674230 7
9 COSM143157019 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.265C>T p.R89W 17:7674221-7674221 7
10 COSM111766786 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.587G>C p.R196P 17:7674944-7674944 7
11 COSM144652630 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.467T>C p.I156T 17:7674947-7674947 7
12 COSM144650760 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.701G>A p.R234H 17:7673802-7673802 7
13 COSM121875541 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.422G>A p.R141H 17:7673802-7673802 7
14 COSM144092363 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.359G>A p.G120E 17:7673784-7673784 7
15 COSM142837551 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.742C>T p.R248W 17:7674221-7674221 7
16 COSM122734399 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.346C>T p.R116W 17:7674221-7674221 7
17 COSM87900157 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.818G>T p.R273L 17:7673802-7673802 7
18 COSM105621872 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.584T>C p.I195T 17:7674947-7674947 7
19 COSM106053434 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.742C>T p.R248W 17:7674221-7674221 7
20 COSM144015040 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.785G>T p.R262L 17:7673802-7673802 7
21 COSM93185256 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.818G>T p.R273L 17:7673802-7673802 7
22 COSM93190437 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.517G>T p.V173L 17:7675095-7675095 7
23 COSM145017944 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.625C>T p.R209W 17:7674221-7674221 7
24 COSM111758868 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.742C>T p.R248W 17:7674221-7674221 7
25 COSM142837352 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.743G>A p.R248Q 17:7674220-7674220 7
26 COSM144087106 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.266G>A p.R89Q 17:7674220-7674220 7
27 COSM145018679 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.707G>T p.C236F 17:7673796-7673796 7
28 COSM121876459 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.346C>T p.R116W 17:7674221-7674221 7
29 COSM93191567 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.587G>C p.R196P 17:7674944-7674944 7
30 COSM144048390 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.678G>C p.M226I 17:7674252-7674252 7
31 COSM142837497 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.733G>A p.G245S 17:7674230-7674230 7
32 COSM144651436 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.625C>T p.R209W 17:7674221-7674221 7
33 COSM105667399 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.711G>C p.M237I 17:7674252-7674252 7
34 COSM144013367 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.710G>A p.R237Q 17:7674220-7674220 7
35 COSM144026584 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.499C>G p.H167D 17:7675080-7675080 7
36 COSM112253879 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.742C>T p.R248W 17:7674221-7674221 7
37 COSM143378524 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.719G>A p.G240E 17:7673784-7673784 7
38 COSM111759630 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.797G>A p.G266E 17:7673823-7673823 7
39 COSM142560553 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.625C>T p.R209W 17:7674221-7674221 7
40 COSM143945376 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.341G>T p.R114L 17:7673802-7673802 7
41 COSM142866376 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.711G>C p.M237I 17:7674252-7674252 7
42 COSM93183281 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.818G>A p.R273H 17:7673802-7673802 7
43 COSM143156843 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.266G>A p.R89Q 17:7674220-7674220 7
44 COSM111797204 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.711G>C p.M237I 17:7674252-7674252 7
45 COSM87898709 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.742C>T p.R248W 17:7674221-7674221 7
46 COSM105620276 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.743G>A p.R248Q 17:7674220-7674220 7
47 COSM122748281 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.136C>G p.H46D 17:7675080-7675080 7
48 COSM106067001 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.532C>G p.H178D 17:7675080-7675080 7
49 COSM145024750 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.400G>T p.V134L 17:7675095-7675095 7
50 COSM144014340 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.791G>T p.C264F 17:7673796-7673796 7
Sources

Expression for Ductal Carcinoma in Situ

About this section
Search GEO for disease gene expression data for Ductal Carcinoma in Situ.
Sources

Pathways for Ductal Carcinoma in Situ

About this section

Pathways related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Disease 66
Show member pathways
 13.77 TP53 ESR1 ERBB2 EGFR CYP19A1 CDH1
2
Signaling by Receptor Tyrosine Kinases 66
12.78 PGR ESR1 ERBB2 EGFR AKT1
3
Malignant pleural mesothelioma 74
12.63 TP53 EGFR CDH1 BRCA1 AKT1
4
Endometrial cancer 74
Show member pathways
 12.59 TP53 ERBB2 EGFR CDH1 BRCA2 AKT1
5
NF-kappaB Pathway 70
Show member pathways
 12.39 TP53 ERBB2 EGFR AKT1
6
Development EGFR signaling pathway 22
Show member pathways
 12.39 TP53 ERBB2 EGFR CDH1 AKT1
7
Hepatocyte growth factor receptor signaling 74
Show member pathways
 12.35 TP53 ESR1 ERBB2 CDH1 AKT1
8
Development Ligand-independent activation of ESR1 and ESR2 22
Show member pathways
 12.26 ESR1 ERBB2 EGFR AKT1
9
Focal adhesion 74
12.23 TNK2 ERBB2 EGFR AKT1
10
MAPK Signaling: Mitogens 65
Show member pathways
 12.17 TP53 ERBB2 EGFR AKT1
11
Colorectal Cancer Metastasis 64
12.13 TP53 EGFR CDH1 AKT1
12
Epithelial to mesenchymal transition in colorectal cancer 74
12.11 TP53 CLDN7 CDH1 AKT1
13
mTOR Signaling 65
12.03 AKT1 EGFR ERBB2 TP53
14
Signaling by ERBB4 66
Show member pathways
 11.99 PGR ESR1 ERBB2 EGFR
15
Breast cancer pathway 74
Show member pathways
 11.99 TP53 PGR ESR1 ERBB2 EGFR BRCA2
16
MAPK Pathway 70
Show member pathways
 11.93 TP53 ERBB2 EGFR AKT1
17
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors 66
Show member pathways
 11.8 ESR1 ERBB2 EGFR
18
BRCA1 Pathway 64
Show member pathways
 11.77 BRCA1 BRCA2 TP53
19
DNA IR-damage and cellular response via ATR 74
11.75 TP53 BRCA2 BRCA1
20
Regulation of Telomerase 61
11.66 ESR1 EGFR AKT1
21
Physico-chemical features and toxicity-associated pathways 74
11.64 AKT1 EGFR ERBB2
22
Glucocorticoid receptor regulatory network 61
11.64 AKT1 KRT14 KRT5 TP53
23
Validated nuclear estrogen receptor alpha network 61
11.63 BRCA1 ESR1 PGR
24
Head and neck squamous cell carcinoma 74
11.6 TP53 ERBB2 EGFR AKT1
25
Hepatitis C and hepatocellular carcinoma 74
11.54 TP53 BRCA1 AKT1
26
Validated transcriptional targets of deltaNp63 isoforms 61
11.47 KRT5 KRT14 BRCA2
27
Pathways affected in adenoid cystic carcinoma 74
11.46 TP53 ERBB2 BRCA1 AKT1
28
Integrated breast cancer pathway 74
11.4 TP53 ESR1 EGFR CYP19A1 CDH1 BRCA2
29
Integrated cancer pathway 74
11.35 TP53 BRCA1 AKT1
30
Ovarian infertility 74
11.31 PGR CYP19A1 AKT1
31
Aurora A signaling 61
11.25 TP53 BRCA1 AKT1
32
Bladder cancer 74
11.22 TP53 ERBB2 EGFR CDH1
33
Extracellular vesicle-mediated signaling in recipient cells 74
11.16 ERBB2 EGFR AKT1
34
a6b1 and a6b4 Integrin signaling 61
11.13 AKT1 CDH1 EGFR ERBB2
35
Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4) 74
10.96 PGR ESR1 ERBB2 EGFR
36
E-cadherin signaling in keratinocytes 61
10.91 EGFR CDH1 AKT1
37
Mammary gland development pathway - Puberty (Stage 2 of 4) 74
10.69 PGR ESR1 ERBB2
38
Relationship between inflammation, COX-2 and EGFR 74
10.66 EGFR CYP19A1
39
Mammary gland development pathway - Involution (Stage 4 of 4) 74
10.66 TP53 CDH1
40
Caloric restriction and aging 74
10.61 TP53 AKT1
41
Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics 60
10.2 ESR1 CYP19A1
Sources

GO Terms for Ductal Carcinoma in Situ

About this section

Cellular components related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear ubiquitin ligase complex GO:0000152 8.92 BRCA2 BRCA1

Biological processes related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular response to epidermal growth factor stimulus GO:0071364 9.85 ERBB2 EGFR AKT1
2 cellular response to indole-3-methanol GO:0071681 9.56 CDH1 BRCA1
3 chordate embryonic development GO:0043009 9.5 BRCA2 BRCA1
4 positive regulation of RNA polymerase II transcription preinitiation complex assembly GO:0045899 9.46 TP53 ESR1
5 cellular response to ionizing radiation GO:0071479 9.43 TP53 BRCA2 BRCA1
6 positive regulation of miRNA maturation GO:1903800 9.4 TP53 EGFR
7 response to UV-A GO:0070141 8.92 EGFR AKT1

Molecular functions related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 10.03 AKT1 BRCA1 BRCA2 CDH1 CLDN7 CT45A10
2 enzyme binding GO:0019899 9.93 TP53 PGR ESR1 EGFR BRCA1 AKT1
3 nitric-oxide synthase regulator activity GO:0030235 9.1 ESR1 EGFR AKT1
Sources

Sources for Ductal Carcinoma in Situ

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....